Bayer, Janssen, M-S, AZ, Sanofi, Lundbeck, UCB fuel €170M EU-wide screening honeypot
This article was originally published in Scrip
Executive Summary
Seven pharmaceutical companies are taking part in a new European public-private drug discovery collaboration under which academia and industry will assemble a pool of hundreds of thousands of compounds as a way of attracting researchers with novel screening approaches and targets. A key part of the move is to develop compounds from academia that are designed to address "difficult and so far intractable" targets.
You may also be interested in...
EU Countries Offered Funding To Contribute to African Regulatory Strengthening
Training projects are intended to strengthen the African regulatory environment, boost the capacity of the African Medicines Agency, facilitate regulatory reliance, and increase joint new drug assessments.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.